ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
August 04, 2020Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 Internati
Pharma Sources Insight January 2025
